Landmarks in hormonal therapy for prostate cancer-Reference-Cited by-同舟云学术

Landmarks in hormonal therapy for prostate cancer

Published:2012-10 Issue: Volume:110 Page:23-29
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Hammerer Peter,Madersbacher Stephan

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2012.11431.x/fullpdf

Reference70 articles.

1. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer;Horwitz;J Clin Oncol,2008

2. Heidenreich A Bolla M Joniau S et al EAU Guidelines on Prostate Cancer 2011 http://www.uroweb.org/gls/pdf/08_Prostate_Cancer%20September%2022nd%202011.pdf

3. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making;Oefelein;Urology,2000

4. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy;Morote;J Urol,2007

5. Decline in bilateral orchiectomy for prostate cancer in Olmsted county, Minnesota, 1956-2000;Melton;Mayo Clinic Proc,2001

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of high molecular weight cytokeratin—A novel feature of aggressive and innate hormone‐refractory prostatic adenocarcinoma;The Prostate;2022-12-28

2. The Impact of Homocysteine on the Risk of Hormone-Related Cancers: A Mendelian Randomization Study;Frontiers in Nutrition;2021-08-24

3. Signalling transduction of O-GlcNAcylation and PI3K/AKT/mTOR-axis in prostate cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2021-07

4. Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions;Molecules;2021-04-12

5. KLF5 Is Crucial for Androgen-AR Signaling to Transactivate Genes and Promote Cell Proliferation in Prostate Cancer Cells;Cancers;2020-03-21